FDA approves ready-to-use oral suspension form of mycophenolate mofetil

Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients ≥3 months of age of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. According to a manufacturer press release, Myhibbin is the only FDA-approved ready-to-use mycophenolate mofetil oral suspension. The product is expected to be commercially available in pharmacies nationwide in the second quarter of 2024.